DE
Therapeutic Areas
Kamada Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Glassia® (IV AAT) | Alpha-1 Antitrypsin Deficiency (AATD) | Approved |
| Inhaled AAT (KMA-001) | Alpha-1 Antitrypsin Deficiency (AATD) | Phase 3 |
| KEDRAB® | Rabies Post-Exposure Prophylaxis | Approved |
| Fibrinogen Concentrate (Human) | Congenital Fibrinogen Deficiency | Phase 3 |
| Anti-SARS-CoV-2 Plasma (Immunoglobulin) | Hospitalized COVID-19 | Phase 1/2 |
| Anti-RhD Immunoglobulin (IVIg) | Immune Thrombocytopenic Purpura (ITP) | Pre-clinical |
| Anti-CD38 Antibody | Oncology (Multiple Myeloma) | Pre-clinical |
Leadership Team at Kamada
AL
Amir London
Chief Executive Officer
GL
Guy Lebowitz
Chief Financial Officer
JB
Joshua Berkman
Chief Business Officer
NB
Nurit Benjamini
Chief Operating Officer
DD
Dr. Dana Biran-Tal
Vice President, Research & Development
DE
Dr. Eyal Rubin
Senior Vice President, Finance & Treasurer
AA
Adi Azaria
Chairman of the Board
C(
Chaime (Chaiko) Orlev
Director
DY
Dr. Yaron Naos
Director
AN
Anat Naschitz
Director